TGFB1 and osteogenesis imperfecta: There have been no reports of the use of any anti-transforming growth factor beta (TGFb) antibody treatment in children with OI; the report of the first use of fresolimumab in adults (NCT03064074) did include analysis of bone biopsies from four children that showed increased TGFb pathway signalling activity [65].